Citations

Clear

6273 citation(s) found for "To, Andrew".

S1596 Comparison of Nutritional Parameters, Efficacy, and Safety of Endoscopic Gastrojejunostomy versus Duodenal Self-Expandable Metal Stent for the Management of Malignant Gastric Outlet Obstruction
Law, Ryan , Bofill-García, Aliana, Bauss, Jacob M. , AbiMansour, Jad P. , Siranart, Noppachai , Simadibrata, Daniel Martin , Storm, Andrew C. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1158-S1158

10.14309/01.ajg.0001035752.19015.60 Get It

S1575 Technique and Success Rate for Removal of a Novel Endoscopic Tack-and-Suture Device
Salameh, Yara , Lemke, Elizabeth, Aggarwal, Manik , Buttar, Navtej , Salameh, Yara , Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1144-S1144

10.14309/01.ajg.0001035668.00026.21 Get It

S998 How Often Does Duodenal Bleeding Manifest as Blood in the Stomach? A Large Retrospective Series
Salameh, Yara , Sayegh, Lea, Aggarwal, Manik , Salameh, Yara , Sayegh, Lea, Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S699-S700

10.14309/01.ajg.0001033360.16687.92 Get It

S820 Metabolomic Profiling Reveals Alterations in Butyrate Metabolism Associated With Anxiety in Working Adults
Gawey, Brent J. , Comba, Yagmur Y., Neish, Andrew S. , Ziegler, T., Smith, Matthew Ryan , Comba, Yagmur Y., Jones, Dean P. , Ziegler, Thomas R.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S562-S562

10.14309/01.ajg.0001032648.58178.37 Get It

S562 Incidence of Young-Onset Barrett’s Esophagus is Increasing: A Population-Based Study From a Multi-Institutional National Database
Vasireddy, Anila , Chandar, Apoorva K., Maravillas, Mart Andrew , Pérez, Jaime A. , Perneth, Sandra Algarin, Leggett, Cadman, Iyer, Prasad G. , Gaddam, Srinivas , Kamboj, Amrit K. , Leggett, Cadman L.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S389-S390

10.14309/01.ajg.0001031616.24587.11 Get It

Determinants of symptom presentation and resolution following concussions in high school sports
Boltz, Adrian J. , Lempke, Landon B. , Rao, Neel , Northam, Weston T. , Collins, Christy L. , Alexander, Andrew , Alexander, Andrew S , Chandran, Avinash S. , Alexander, Andrew S., DiPietro, Loretta

Mayo Clinic

Research in Sports Medicine | October 23, 2024 | Volume: 33 | Issue: 1 | Pages: 72-86

10.1080/15438627.2024.2414972 | PMID 39439229 Get It

Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease
Asatryan, Babken , Murray, Brittney , Tadros, Rafik , Shah, Ravi A. , Dabbagh, Ghaith Sharaf , Landstrom, Andrew P. , Dobner, Stephan , Munroe, Patricia B. , Haggerty, Christopher M. , Owens, Anjali , Semsarian, Christopher , Barth, Andreas S. , Roden, Dan M. , Ware, James S. , Investigators, the Genotype‐First Approach, Shah, Ravi A , Sharaf Dabbagh, Ghaith , Landstrom, Andrew P , Dobner, Stephan , Munroe, Patricia B , Haggerty, Christopher M , Medeiros-Domingo, Argelia , Owens, Anjali T , Kullo, Iftikhar J , Semsarian, Christopher , Reichlin, Tobias , Barth, Andreas S , Roden, Dan M. , James, Cynthia A , Ware, James S , Chahal, Choudhary Anwar A , Asatryan, Babken , Tadros, Rafik , Rieder, Marina , Medeiros‐Domingo, Argelia , Kullo, Iftikhar J. , James, Cynthia A. , Chahal, C. Anwar A. , Investigators, the Genotype‐First Approach

Mayo Clinic

Journal of the American Heart Association | October 18, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1161/jaha.123.033557 | PMID 39424414 Get It

Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.
Neurodegenerative fluid biomarkers are enriched in human cervical lymph nodes
Al‐Diwani, Adam , Provine, Nicholas M. , Murchison, Andrew G. , Laban, Rhiannon , Swann, Owen , Koychev, Ivan , Sheerin, Fintan , Mesquita, Sandro Dá , Zetterberg, Henrik , Irani, Sarosh R. , Zetterberg, Henrik , Klenerman, Paul , Irani, Sarosh R , Da Mesquita, Sandro , Heslegrave, Amanda

Mayo Clinic

Brain | October 18, 2024 | Volume: 148 | Issue: 2 | Pages: 394-400

10.1093/brain/awae329 | PMID 39432679 Get It

Abstract In animal models, brain neurodegeneration biomarkers drain into cervical lymph nodes (CLNs), and this drainage function is reduced with ageing. If this occurred in humans, CLNs may provide a readily accessible measure of this aspect of protein clearance. We tested this hypothesis in people using ultrasound-guided fine needle aspiration. We measured amyloid-beta 40 and 42, phosphorylated tau 181 (pTau181), glial fibrillary acidic protein and neurofilament light using single molecule array in CLN aspirates and plasma from: (i) a discovery cohort of 25 autoimmune patients; and (ii) plasma, CLNs and capillary blood in four healthy volunteers, an optimization cohort. Ultrasound-guided fine needle aspiration was well-tolerated by all participants. In both cohorts, all biomarkers were detected in all plasma and CLN samples, other than neurofilament light (8/17 of discovery cohort). CLN biomarker concentrations were significantly greater than plasma concentrations for all except neurofilament light, most markedly for pTau181 (266-fold; P < 0.02), whose CLN concentrations decreased with age (Spearman r = −0.66, P = 0.001). This study presents the first evidence that neurodegenerative biomarkers are detectable in human CLNs. Raised CLN:plasma biomarker ratios suggest their concentration in CLNs may offer a distinct compartment for minimally-invasive measurement of brain clearance and lymphatic drainage, with potential applicability to study of ageing and future clinical trials.
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj, Senthil , Patel, Shachi, McGarrah, Robert W. , Jones, Philip G. , Kwee, Lydia Coulter , Windsor, Sheryl L. , Ilkayeva, Olga , Muehlbauer, Michael J. , Newgard, Christopher B. , Kitzman, Dalane W. , Inzucchi, Silvio E. , Mentz, Robert J. , Kosiborod, Mikhail , Shah, Svati H. , Sauer, Andrew J , McGarrah, Robert , Jones, Philip G , Kwee, Lydia Coulter , Windsor, Sheryl L , Ilkayeva, Olga , Muehlbauer, Michael J , Newgard, Christopher B , Borlaug, Barry A , Kitzman, Dalane W , Shah, Sanjiv J , Margulies, Kenneth B. , Husain, Mansoor , Inzucchi, Silvio E , McGuire, Darren K , Lanfear, David E , Javaheri, Ali , Umpierrez, Guillermo E. , Mentz, Robert J , Sharma, Kavita , Kosiborod, Mikhail N , Shah, Svati , Borlaug, Barry A. , Husain, Mansoor , McGuire, Darren K. , Sharma, Kavita

Mayo Clinic

Circulation: Heart Failure | October 18, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.124.011980 | PMID 39421941 Get It

BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar effects have not been observed in HF with preserved ejection fraction. We explore whether metabolic effects of SGLT2is vary across the left ventricular ejection fraction spectrum and their relationship with cardiometabolic end points in 2 randomized trials of dapagliflozin in HF. METHODS: Metabolomic profiling of 61 metabolites was performed in 527 participants from DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) and PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction HF; 12-week, placebo-controlled trials of dapagliflozin in HF with reduced ejection fraction and HF with preserved ejection fraction, respectively). Linear regression was used to assess changes in principal components analysis–defined metabolite factors with treatment from baseline to 12 weeks, as well as the relationship between changes in metabolite clusters and HF-related end points. RESULTS: The mean age was 66±11 years, 43% were female, and 33% were self-identified as Black. Two principal components analysis–derived metabolite factors (which were comprised of ketone and short-/medium-chain acylcarnitines) increased with dapagliflozin compared with placebo. Ketosis (defined as 3-hydroxybutyrate >500 μM) was achieved in 4.5% with dapagliflozin versus 1.2% with placebo ( P =0.03). There were no appreciable treatment effects on amino acids, including branched-chain amino acids. Increases in several acylcarnitines were consistent across LVEF ( P interaction >0.10), whereas the ketogenic effect diminished at higher LVEF ( P interaction =0.01 for 3-hydroxybutyrate). Increases in metabolites reflecting mitochondrial dysfunction (particularly long-chain acylcarnitines) and aromatic amino acids and decreases in branched-chain amino acids were associated with worse HF-related outcomes in the overall cohort, with consistency across treatment and LVEF. CONCLUSIONS: SGLT2is demonstrate common (fatty acid) and distinct (ketogenic) metabolic signatures across the LVEF spectrum. Changes in key pathways related to fatty acid and amino acid metabolism are associated with HF-related end points and may serve as therapeutic targets across HF subtypes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifiers: NCT03030235 and NCT02653482.